Valye reports for unlimited access

Union Bankshares, Inc. operates a single banking segment focused on providing financial services to retail consumers, small businesses, municipalities, agricultural producers, and the tourism industry primarily in Vermont and New Hampshire. The company offers deposit products such as checking, savings, money market accounts, certificates of deposit, and individual retirement accounts, as well as lending products including commercial, real estate, municipal, and consumer loans. It also provides fiduciary and asset management services through its Wealth Management Group. The loan portfolio is diversified but has significant exposure to real estate in its regional markets. The company manages credit risk through conservative lending policies, loan review programs, and quality control measures. Union Bankshares reported net income growth in 2025 driven by higher net interest income and noninterest income, despite increased noninterest expenses. The company maintains strong capital and liquidity positions with access to multiple funding sources and credit lines. Dividend payments have been consistent, reflecting a balanced approach to capital allocation.

Leapfrog Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in June 2025. Its business model is to identify and acquire a target company, focusing on strategic assets in the international energy supply chain and critical minerals sectors, including related infrastructure. The company aims to leverage its management team's extensive experience and proprietary networks to source acquisition targets with established operations, growth potential, and competitive moats. It completed its IPO in December 2025, raising gross proceeds of approximately $143.75 million plus private placements. The company holds these funds in a trust account earning interest until an initial business combination is consummated. It has a 24-month window from IPO to complete the combination. Until then, it does not generate operating revenues and incurs general and administrative expenses. The company provides shareholders with redemption rights upon completion of the business combination. Recent corporate developments include amendments to its charter and updates on the business combination process.

Starwood Real Estate Income Trust, Inc. is a publicly reporting entity with financial disclosures through SEC filings. The company reported significant net losses for fiscal year 2025 and maintains substantial cash reserves. It declares monthly distributions to multiple classes of common stock. The company’s cybersecurity risk management is comprehensive, involving internal controls, employee training, third-party assessments, and board-level oversight. No material legal proceedings were reported as of the end of 2025. Specific details on the company’s sector, industry, and business model are not publicly disclosed in the available filings.

Skyline Bankshares, Inc. is a bank holding company headquartered in Floyd, Virginia, operating through its wholly-owned subsidiary Skyline National Bank. The company offers a wide range of retail and commercial banking services including real estate, commercial, agricultural, and consumer loans. It serves multiple counties in Virginia, North Carolina, and Tennessee through 28 full-service banking offices and 2 loan production offices. The company has grown through mergers, notably acquiring Great State Bank in 2018 and Johnson County Bank in 2024, expanding its geographic reach. The bank's loan portfolio is heavily weighted toward real estate loans, which constitute the majority of its interest earning assets. Deposits, primarily core deposits, are the main funding source. The company operates in a competitive environment with larger banks, credit unions, fintech firms, and other financial intermediaries. It is subject to extensive federal and state regulation and maintains capital adequacy requirements.

Crawford & Co is a global provider of claims management and related services primarily serving the property and casualty insurance markets. The company operates through four main segments: North America Loss Adjusting, International Operations, Broadspire, and Platform Solutions. Its services include claims adjusting, medical and claims management, and inspection services. The company’s revenues and operating earnings vary by segment, with recent growth in North America Loss Adjusting, International Operations, and Broadspire, and a decline in Platform Solutions due to reduced staff augmentation and transfer of inspection services. The company maintains liquidity through cash reserves and credit facilities and manages defined benefit pension plans in multiple countries.

Ollie's Bargain Outlet Holdings, Inc. operates as an off-price retailer offering brand name household products at prices up to 70% below traditional retailers. Founded in 1982, the company employs a flexible buying model focused on closeout and excess inventory from suppliers worldwide. As of January 31, 2026, Ollie's operates 645 stores across 34 states, primarily in the eastern and central U.S., with a contiguous unit growth strategy combining organic store openings and acquisitions of bankrupt retailers' locations. The company supports its retail operations through distribution centers located in York, PA; Commerce, GA; Lancaster, TX; and Princeton, IL. Its business model emphasizes low pricing, opportunistic buying, and a treasure hunt shopping experience. Marketing primarily uses printed flyers, accounting for over 40% of advertising spend, alongside mailers, email campaigns, and broadcast media. The company operates on a fiscal year ending January 31 and reported net income of $240.6 million for fiscal 2025. Liquidity remains strong with cash and equivalents of $259.7 million and a current ratio of 2.41 as of January 31, 2026. Capital expenditures focus on new store openings, lease acquisitions, store resets, distribution center expansions, and IT investments. The company also maintains a share repurchase program authorized for up to $700 million.

Intellicheck, Inc. delivers digital identity validation and fraud prevention solutions across North America, focusing on KYC fraud, age verification, and access control. Its software reads and authenticates encoded data on driver's licenses, non-driver IDs, military IDs, and passports, integrating facial biometrics and risk scoring to enhance security. The company offers multiple product platforms including mobile apps, portals, APIs, and white-label solutions, primarily on a SaaS basis. Intellicheck targets commercial sectors such as retail, financial services, and hospitality, as well as government and law enforcement agencies. The company holds multiple patents and continuously updates its technology to comply with evolving ID formats and regulations. Intellicheck does not manufacture hardware but uses commercial off-the-shelf devices integrated with its software. Customer concentration is notable, with the top ten customers accounting for 77% of revenues in 2025. The company reported profitability in 2025 with positive net income and maintains strong liquidity ratios [S1].

Burlington Stores, Inc. is a national off-price retailer founded in 1972, offering branded merchandise at everyday low prices. The company operates over 1,200 stores across 46 states, Washington D.C., and Puerto Rico, with a product mix spanning apparel, accessories, home goods, and more. Burlington pursues a flexible buying strategy focused on in-season and opportunistic purchases to maintain inventory freshness and value. The company supports its operations with six major distribution centers and multiple warehousing facilities. Its workforce exceeds 83,000 associates, with a strong emphasis on diversity, inclusion, and continuous learning. Burlington targets value-conscious, brand-aware customers primarily aged 25-49 in metropolitan areas. Marketing efforts combine traditional and digital channels to drive store traffic. The retail environment is highly competitive and seasonal, with sales influenced by weather and holiday periods. Fiscal 2025 financials show robust revenue and profitability, with liquidity ratios indicating adequate short-term financial health [S1].

SentinelOne Inc is a technology company specializing in cybersecurity software infrastructure. It offers an AI-powered platform designed to provide endpoint and cloud security solutions. The company distributes its products primarily through a broad network of channel partners, including resellers, managed service providers, and original equipment manufacturers. SentinelOne has experienced rapid growth in its customer base and employee count, expanding its operations domestically and internationally. The company invests heavily in research and development, sales, and marketing to enhance its platform and expand into adjacent markets and geographies. Despite significant revenue growth, SentinelOne has a history of net losses and an accumulated deficit, reflecting ongoing investments and operating expenses. The company faces intense competition from larger, more established cybersecurity firms with broader product offerings and resources. SentinelOne's platform must effectively interoperate with diverse customer IT infrastructures, and deployment challenges can impact customer retention. The company is subject to various risks including market volatility, regulatory compliance, cybersecurity incidents, and operational challenges related to scaling and integration.

AEVA TECHNOLOGIES INC was founded in 2017 by former Apple engineers and focuses on developing the world's first 4D LiDAR-on-chip technology using proprietary Frequency Modulated Continuous Wave (FMCW) sensing. This technology measures velocity, depth, reflectivity, and inertial motion for every pixel, providing a significant advantage over traditional 3D Time-of-Flight LiDAR systems. AEVA's 4D LiDAR is integrated on a silicon photonics chip, enabling a compact form factor suitable for volume manufacturing. The technology offers long-range detection up to 500 meters, immunity to interference from other LiDAR or sunlight, and operates at low optical power, enhancing laser safety and performance in inclement weather. AEVA's product portfolio includes the Aeva Atlas™ and Atlas Ultra sensors for automotive applications, the Eve™ 1 line for industrial automation, and the Atlas Orion sensor for smart infrastructure and security. The company targets multiple markets including passenger vehicles, trucks, new mobility platforms, industrial automation, consumer devices, and security. AEVA works closely with customers on development and commercialization, with many customers currently using prototypes and engineering services. The company is expanding manufacturing capacity through third-party manufacturers to meet anticipated demand and is engaged with automotive OEMs and Tier 1 suppliers for integration of its solutions into vehicle platforms.

First Seacoast Bancorp, Inc. is the holding company for First Seacoast Bank, a federally-chartered savings bank headquartered in Dover, New Hampshire. The bank operates five full-service offices in the New Hampshire Seacoast area and serves adjacent York County, Maine. The company focuses on traditional banking activities including deposit taking and lending, with a loan portfolio concentrated in one- to four-family residential real estate loans, commercial real estate, commercial and industrial loans, home equity loans, and consumer loans. The company also offers investment management services through FSB Wealth Management, a division of the bank. The company emphasizes net interest income and customer service fees as primary revenue sources. It competes in a highly competitive regional financial services market against larger banks and non-bank financial service providers. The company maintains regulatory compliance and capital adequacy, with a well-capitalized status as of December 31, 2025.

Dollar General Corporation is a discount retailer operating primarily in the United States, offering a broad assortment of consumables, seasonal items, home products, and apparel at low prices. The company focuses on serving value-conscious consumers through a network of stores located mainly in rural and suburban areas. Dollar General's business model emphasizes cost efficiency, high inventory turnover, and a value proposition centered on convenience and affordability. The company maintains active oversight of operational risks including cybersecurity, with the Board's Audit Committee engaged in enterprise risk management and regular review of risk mitigation strategies [S1].

Victoria's Secret & Co. operates globally recognized intimate apparel brands Victoria's Secret and PINK, complemented by a beauty business and the direct-to-consumer brand Adore Me. The company sells through retail stores in North America and China, digital channels, and international partners across approximately 70 countries. Its business model emphasizes product innovation, brand differentiation, and omnichannel customer engagement. The company faces challenges from tariffs and a recent IT security incident but continues to execute a strategic growth plan called 'Path to Potential' focused on bra leadership, revitalizing PINK, expanding beauty, and evolving go-to-market strategies. Financially, the company reported increased net sales and gross profit in 2025, with solid liquidity and cash flow generation.

Milestone Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development and commercialization of etripamil, a nasal spray treatment for paroxysmal supraventricular tachycardia (PSVT). The company’s lead product, CARDAMYST, received FDA approval in December 2025 as the first self-administered nasal spray for PSVT and has since been launched commercially. Milestone does not own manufacturing facilities and relies on third-party manufacturers, with some suppliers located internationally, including China. The company has licensed rights for etripamil nasal spray delivery in China and related territories to Corxel, an affiliate of RTW Investments, and has monetized future royalties through a $75 million upfront payment from RTW. Financially, Milestone reported a net loss of $63.1 million for the fiscal year ended December 31, 2025, with strong liquidity ratios indicating a solid cash position. The company faces risks from regulatory approval processes, international trade policies, and evolving healthcare legislation affecting drug pricing and reimbursement.

InflaRx N.V. is a clinical-stage biopharmaceutical company listed on Nasdaq since 2017. The company primarily engages in research and development of therapeutic candidates, with a focus on inflammatory diseases. Its main product candidates include vilobelimab and izicopan, which are in various stages of clinical trials. InflaRx has not generated significant product revenue and relies on equity financing, government grants, and collaborations to fund operations. The company reported a net loss of €45.6 million for 2025 and held cash and short-term investments totaling approximately €46.4 million at year-end 2025. It has received regulatory notices related to its stock price and continues to manage risks related to clinical development, financing, and cybersecurity [S1][N1][N2].

Ermenegildo Zegna N.V. is a luxury fashion group with a leading position in high-end menswear and a portfolio of three complementary brands: ZEGNA, Thom Browne, and TOM FORD FASHION. The Group's vertically integrated supply chain, known as the Filiera, includes some of Italy's finest textile producers and luxury manufacturing facilities. The Group designs, produces, markets, and distributes luxury menswear, womenswear, footwear, leather goods, and accessories globally. It operates primarily through a direct-to-consumer (DTC) channel, comprising 471 directly operated stores worldwide as of December 31, 2025, supplemented by wholesale distribution in over 80 countries. The Group's revenues for 2025 were approximately €1.92 billion, with a net profit of €109.5 million. The Group's business is influenced by macroeconomic factors, consumer confidence, and international tourism, which affect discretionary spending on luxury goods. The Group has been focusing on expanding and strengthening its DTC channel, including converting wholesale stores to DTC and opening new locations. The acquisition of TOM FORD FASHION in 2023 expanded the Group's brand portfolio and product offerings. The Group maintains a net cash surplus and liquidity ratios indicating financial stability. Risks include macroeconomic uncertainty, inflationary pressures, geopolitical developments, and ongoing legal proceedings related to trademark disputes.

Belpointe PREP, LLC is a Delaware limited liability company and the successor to Belpointe REIT, Inc. It is externally managed by an affiliate of its sponsor and operates as a qualified opportunity fund investing primarily in commercial real estate and related assets within qualified opportunity zones. The company’s portfolio includes commercial, mixed-use, multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, data centers, and solar projects across the United States. It has two reportable segments: Commercial and Mixed-use. The company’s Class A units trade on the NYSE American under the ticker 'OZ'. It has raised significant capital through public offerings and calculates NAV quarterly. The company does not currently pay distributions and manages leverage with a target property-level range of 50-70%.

Pelican Acquisition Corp was incorporated in July 2024 in the Cayman Islands as a blank check company with the purpose of effecting a merger, share exchange, asset acquisition, or similar business combination. The company completed its initial public offering in May 2025, raising gross proceeds of $86.25 million plus a private placement, with funds held in a trust account for the benefit of public shareholders. The company’s sole activity since IPO has been identifying and evaluating acquisition candidates. In September 2025, it entered into a definitive business combination agreement with Greenland Exploration Limited and March GL Company. Upon closing, the company will domesticate to Texas and rename to Greenland Energy Company, with an expected Nasdaq listing. The management team comprises experienced professionals with backgrounds in real estate, law, corporate management, and international business. The company faces competition from other SPACs and investment entities in sourcing acquisition targets and must comply with Nasdaq rules requiring the initial business combination to meet minimum valuation thresholds. The company’s financial position as of January 31, 2026, shows limited liquidity and no operating revenue.

York Space Systems Inc. is a leading U.S. space and defense prime contractor focused on delivering mission-critical spacecraft and software solutions for national security and commercial markets. The company provides a vertically integrated technology stack encompassing spacecraft design, production, integration, and operation, enabling rapid deployment and lifecycle management of satellite constellations. York's spacecraft platforms—S-CLASS, LX-CLASS, and M-CLASS—are modular and share substantial hardware and software commonality, facilitating scalable, cost-effective solutions across a broad range of mission requirements. Proprietary software suites support autonomous mission planning, flight control, and ground operations, integrated with a global network of more than 45 ground antennas. York's business model includes recurring revenue from software and services alongside hardware replacement cycles. The company completed its IPO in January 2026 and maintains a significant backlog of contracts primarily with U.S. government defense customers.

Firefly Aerospace Inc. is a publicly traded aerospace company with recent SEC filings disclosing financial results for the fiscal year ended December 31, 2025. The company maintains substantial liquidity with cash and short-term investments totaling over $890 million and a current ratio above 4.5. Despite significant net losses reported in 2025, Firefly Aerospace is actively managing its capital structure, including an expanded revolving credit facility. Operationally, the company has appointed a new COO to lead production scaling efforts. Public disclosures do not provide detailed descriptions of the company's products, customers, or industry classification.

QIAGEN N.V. is a global provider of molecular diagnostics and life sciences tools, focusing on sample and assay technologies. The company files comprehensive annual (20-F) and quarterly (6-K) reports with the SEC, detailing its financial performance, business strategy, and operational environment. It emphasizes adjusted financial results to provide clarity on ongoing core operations, excluding certain non-recurring or non-operational costs. The company reported strong liquidity and profitability metrics for the fiscal year ended December 31, 2025. Recent corporate developments include an acquisition agreement for Parse Biosciences and a synthetic share repurchase plan. Leadership changes occurred with the CEO stepping down in late 2025. The company operates in a regulated environment with ongoing research and development efforts and holds significant intellectual property assets [S1][S2].

Cellectis S.A. operates as a clinical-stage biotechnology company focused on developing gene-edited allogeneic CAR T-cell therapies (UCART) for cancer treatment and gene therapy candidates for other diseases. Its proprietary gene-editing technology enables the creation of off-the-shelf CAR T-cell products derived from healthy donors, designed to improve safety and efficacy. The company manages its operations primarily through its Therapeutics segment, following the deconsolidation of its former Plants segment. Cellectis collaborates with partners such as AstraZeneca under joint research and collaboration agreements, which contribute significantly to its revenues. The company sponsors clinical trials for its UCART candidates and continues to develop manufacturing capabilities in France and the United States. It has incurred net losses historically, reflecting ongoing investment in research and development and clinical programs. Cellectis' securities are listed on Nasdaq and Euronext Growth Paris.

Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases. Its commercial portfolio includes eight FDA-approved products targeting endocrinology and metabolic rare diseases, such as INCRELEX® for severe primary IGF-1 deficiency, ALKINDI SPRINKLE® and KHINDIVI™ for adrenal insufficiency, GALZIN® for Wilson disease, and others for phenylketonuria, NAGS deficiency, homocystinuria, and tyrosinemia type 1. The company also has five late-stage development candidates, including ET-600 with a PDUFA date in early 2026, and others in clinical or preclinical stages. Eton leverages its business development expertise to acquire and advance under-appreciated assets, employs regulatory knowledge particularly in the FDA 505(b)(2) pathway, and maintains internal commercial operations with a sales force targeting specialty physicians and patient advocacy groups. Manufacturing is outsourced to qualified third-party CMOs in the US and Europe. The company reported $79.95 million in revenues for 2025, with significant growth in product sales and licensing revenue, but a net loss of $4.6 million. Cash and liquidity ratios indicate a moderate liquidity position as of year-end 2025 [S1].

Biofrontera Inc. develops, manufactures, and commercializes pharmaceutical products for dermatological conditions, focusing on photodynamic therapy (PDT). Its main products, Ameluz and the RhodoLED lamp series, treat actinic keratosis, a skin condition with pre-cancerous lesions. The company sells directly to dermatology offices in the U.S. and manages clinical trials through its subsidiary Discovery. In 2025, Biofrontera acquired full U.S. rights to Ameluz and RhodoLED and sold its Xepi product line asset. The company aims to expand sales in the U.S., pursue label extensions, and strategically manage its portfolio to support growth. It employs 92 people across the U.S. and Germany and maintains a diverse customer base. Financially, it reported a net loss in 2025 with moderate liquidity ratios. Recent clinical data and FDA regulatory progress support its product pipeline.

Assembly Biosciences, Inc. is a biotechnology company developing therapeutics targeting serious viral diseases with a focus on recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV). The company’s clinical-stage pipeline includes two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes (ABI-1179 and ABI-5366), an orally bioavailable HDV entry inhibitor (ABI-6250), a next-generation capsid assembly modulator (ABI-4334) for HBV, and a broad-spectrum non-nucleoside polymerase inhibitor (ABI-7272) targeting transplant-related herpesviruses. Assembly has a collaboration agreement with Gilead Sciences, which exercised its option to license the HPI program in December 2025. The company reported positive Phase 1a/b clinical data for its HPI candidates, showing potent antiviral activity, favorable pharmacokinetics supporting once-weekly or once-monthly oral dosing, and good safety profiles. Assembly has no approved products and finances operations through equity and collaboration revenues. As of December 31, 2025, the company held approximately $248.1 million in liquid assets and reported a net loss of $6.12 million for the year. The company outsources manufacturing and employs 73 people primarily in South San Francisco, California.

RCI Hospitality Holdings, Inc. is a holding company operating live adult entertainment nightclubs and a military-themed restaurant and bar concept called Bombshells. As of September 30, 2025, it operated 71 establishments across 15 states, including 59 nightclubs and 11 Bombshells locations. The Nightclubs segment generates revenue primarily from alcoholic beverages, service charges, and food and merchandise sales, with a gross margin of approximately 88.6% in fiscal 2025. The Bombshells segment focuses on a dining and entertainment experience with military-themed décor and uniforms, generating revenue from alcoholic beverages and food, with a gross margin of about 76.1%. The company also operates a Media Group serving the adult nightclub and retail industries and licenses an energy drink brand. The company launched a five-year Back-to-Basics strategy in December 2024 to improve existing operations and allocate free cash flow among acquisitions, share buybacks, and dividends. It reported consolidated revenues of $279.4 million and diluted EPS of $1.23 for fiscal 2025. The company is publicly traded on Nasdaq under the ticker RICK.

Zura Bio Ltd is a clinical-stage biotechnology company developing novel and differentiated medicines targeting autoimmune and inflammatory diseases with significant unmet medical needs. The company focuses on immune-mediated diseases supported by translational and clinical evidence. Its lead product candidate, tibulizumab, is in ongoing Phase 2 clinical trials for systemic sclerosis (SSc) and hidradenitis suppurativa (HS). The company also has additional clinical-stage assets including crebankitug and torudokimab. Zura Bio does not own manufacturing facilities but relies on contract manufacturing organizations and contract research organizations to conduct its clinical development programs. The company completed a Business Combination in March 2023 and trades on Nasdaq under the ticker ZURA. It is classified as an emerging growth company and a smaller reporting company under SEC definitions. The company has not generated revenue to date and has incurred operating losses since inception.

Kohl's Corp operates as a retail company offering a broad range of merchandise including women's, men's, children's apparel, footwear, accessories, and home products. The company has a significant digital sales channel, which accounted for 29% of net sales in 2025. Kohl's operates over 1,100 Sephora at Kohl's shop-in-shop locations, enhancing its product offerings. The company manages inventory carefully to optimize gross margin and has been closing underperforming stores and e-commerce fulfillment centers to improve operational efficiency. Kohl's capital allocation focuses on investing in growth, paying dividends, reducing debt, and share repurchases. The company maintains liquidity with a current ratio of 1.46 and a strong cash position as of January 31, 2026.

Sprinklr, Inc. provides a Unified Customer Experience Management (Unified-CXM) platform designed to help enterprises manage customer interactions across digital and traditional channels. The AI-native platform supports collaboration across customer-facing teams such as Customer Service and Marketing, enabling seamless, personalized customer journeys. The platform processes massive volumes of conversational data daily and integrates AI capabilities including machine learning and large language models to deliver insights and automation. Sprinklr offers four main product suites: Service, Social, Insights, and Marketing, all unified on a single scalable platform with extensive integrations and compliance certifications. The company serves a global customer base across industries, including a significant portion of Fortune 100 companies, with a focus on expanding within existing customers and attracting new enterprise clients. The business model relies primarily on subscription revenue with additional professional services. Sprinklr maintains a direct sales organization supported by a diverse partner ecosystem. The company reported $857.2 million in revenue and $22.9 million net income for fiscal year 2026, with a strong liquidity position and ongoing investments in product innovation and market expansion [S1].

Rubrik, Inc. operates as a cybersecurity company focused on securing data and accelerating AI transformation through its proprietary Zero Trust Data Security platform. The company’s core offerings are the Rubrik Security Cloud (RSC), a cloud-native SaaS platform securing data across enterprise, cloud, SaaS, unstructured data, and identity providers, and the Rubrik Agent Cloud (RAC), an AI operations platform for managing AI agent lifecycle and mitigating risks. Rubrik’s platform architecture integrates time-series data and metadata with AI and machine learning to deliver cyber resilience, threat detection, and rapid recovery capabilities. The company employs a land and expand sales strategy, selling subscriptions primarily through direct sales and a partner ecosystem. Rubrik serves a broad customer base across multiple industries and geographies, with a focus on expanding SaaS solutions, innovating product leadership especially in generative AI security, and growing its global footprint. The company reported net losses in fiscal 2026 and maintains moderate liquidity. Key risks include market adoption challenges, competition, transition to SaaS revenue recognition, customer retention, and debt servicing risks.

Satellogic Inc. operates in the NewSpace sector as a vertically integrated Earth observation company. It designs, manufactures, and operates a constellation of high-resolution satellites to provide geospatial data and analytics. The company’s business is organized into two main lines: Data & Analytics, which includes products like Aleph Observer for persistent site monitoring and Constellation as a Service, and Space Systems, which involves satellite sales and turnkey space programs. Satellogic’s technology features patented camera designs that capture significantly more imagery than competitors, a non-ITAR design facilitating sovereign satellite programs, and AI-enabled onboard analytics. The company’s constellation includes 17 operational satellites and two in commissioning as of December 31, 2025, with plans for an AI-First Merlin constellation and a NextGen platform with 30cm-class resolution. Revenues in 2025 were $17.7 million, primarily from government, defense, and intelligence customers, with a growing commercial focus. Satellogic maintains strong liquidity with $94.4 million in cash and equivalents and a current ratio above 5. The company has recently raised capital through registered direct offerings and announced further share offerings. Its sales cycle is long and involves significant effort, focusing on expanding government and commercial customer bases globally.

Snail, Inc. is a leading global independent developer and publisher of interactive digital entertainment across consoles, PCs, and mobile devices. Its flagship ARK franchise is a top-ranked sandbox survival game with over 108.6 million installs and substantial daily active users. The company operates three publishing labels targeting diverse market segments, including AAA and indie titles. Snail utilizes proprietary technology such as a versatile game engine, advanced server infrastructure, AI-driven development tools, and a micro-influencer marketing platform called NOIZ. The company fosters collaborative partnerships with development studios, providing capital, technology, and marketing support while preserving creative autonomy. In 2025, Snail released multiple ARK DLC expansions, expanded its mobile footprint, acquired new games, and advanced initiatives in Film, TV, and digital assets including a proprietary stablecoin. The company reported $81.2 million in net revenue and a net loss of $27.2 million for 2025, with liquidity ratios indicating current challenges. Snail’s business model is heavily reliant on the ARK franchise and third-party platform providers for distribution and monetization.

ONE Group Hospitality, Inc. is a hospitality company operating multiple restaurant brands including STK, Benihana, Kona Grill, and RA Sushi. The company operates 158 venues across North America, Europe, and the Middle East, including owned, managed, licensed, and franchised locations. STK is positioned as a modern American steakhouse with a high-energy social atmosphere, while Benihana offers interactive teppanyaki dining experiences. The company emphasizes a capital-light growth strategy, expanding through franchising and management agreements. Marketing efforts leverage digital, social media, and local advertising to build brand awareness and drive customer traffic. The business is subject to seasonal fluctuations and intense competition from other upscale dining and hospitality concepts. The company reported $805.7 million in revenue and a net loss of $92.2 million for fiscal 2025, with liquidity ratios indicating tight short-term financial flexibility as of year-end 2025.

GENELUX Corp focuses on developing next-generation oncolytic viral immunotherapies targeting aggressive and difficult-to-treat tumors. Its lead product candidate, Olvi-Vec, is a genetically modified vaccinia virus designed to selectively kill tumor cells and stimulate a personalized immune response. The company is conducting multiple clinical trials, including a Phase 3 registrational trial in platinum-resistant/refractory ovarian cancer, a Phase 2 trial in recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China for recurrent small cell lung cancer. GENELUX operates a cGMP manufacturing facility in San Diego and has a strategic licensing and development partnership with Newsoara BioPharma for the Chinese market. The company has not yet commercialized any products and is building its capabilities for potential future commercialization.

American Battery Materials, Inc. operates as a U.S.-based renewable energy company specializing in the extraction, refinement, and distribution of lithium and magnesium minerals. The company holds 743 placer mining claims in the Lisbon Valley of Utah, acquired initially in 2021 and expanded in 2023. It is currently in the exploration stage with no commercial production or mineral reserves established. The company focuses on Direct Lithium Extraction (DLE) technology, which offers environmental and operational advantages over traditional mining methods. It has engaged technical consultants and plans to conduct extensive testing and resource estimation to advance its projects. The company has no current customers or off-take agreements and intends to use intermediaries for sales. It operates with a small team and emphasizes ESG principles. The lithium and magnesium markets are critical to U.S. national security, with government initiatives supporting domestic production. However, the company faces significant liquidity constraints and continues to incur losses while relying on capital markets for funding.

Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for difficult-to-treat cancers, with a current emphasis on solid tumors. The company acquires rights to technologies through licensing or ownership interests, funds research and development, and aims to either out-license or commercialize these technologies. Mustang Bio’s development pipeline includes MB-101, a CAR T-cell therapy targeting IL13Rα2, and MB-108, an HSV-1 oncolytic virus, which are being developed in partnership with City of Hope National Medical Center and Nationwide Children’s Hospital. The combination therapy MB-109 is under regulatory review with the FDA, and clinical trials are planned. Mustang Bio has no approved products and has not generated revenue from product sales. The company has taken corporate actions including a reverse stock split, facility exit, asset divestment, and public offerings to support its operations and Nasdaq listing compliance.